ABSTRACT: The bone-implant interface of cementless orthopedic implants can be described as a series of uneven sized gaps with discontinuous areas of direct bone-implant contact. Bridging these voids and crevices by addition of an anabolic stimulus to increase new bone formation can potentially improve osseointegration of implants. Bone morphogenetic protein 2 (BMP-2) stimulates osteoblast formation to increase new bone formation but also indirectly stimulates osteoclast activity. In this experiment, we investigate the hypothesis that osseointegration, defined as mechanical push-out and histomorphometry, depends on the dose of BMP-2 when delivered as an anabolic agent with systemic administration of the anti-resorptive agent zoledronate to curb an increase in osteoclast activity. Four porous coated titanium implants (one with each of three doses of surface-applied BMP-2 (15 mg; 60 mg; 240 mg) and untreated) surrounded by a 0.75 mm empty gap, were inserted into the distal femurs of each of twelve canines. Zoledronate IV (0.1 mg/kg) was administered 10 days into the observation period of 4 weeks. Bone-implant specimens were evaluated by mechanical push-out test and histomorphometry. The 15 mg implants had the best fixation on all mechanical parameters and largest surface area covered with new bone compared to the untreated, 60 and 240 mg implants, as well as the highest volume of new bone in the implant gap compared to 60 and 240 mg implants. The results in a canine implant model demonstrated that a narrow range of BMP-2 doses have opposite effects in bridging an empty peri-implant gap with bone, when combined with systemic zoledronate. ß
Introduction of a bone anabolic stimulus to increase new bone formation, in areas of close but not intimate bone implant contact, should in theory improve osseointegration and thus implant fixation. 5, 6 Several bone morphogenetic proteins (BMPs) belonging to the transforming growth factor-beta (TGF-ß) superfamily are known. Some have osteoinductive potential such as BMP-2, BMP-7, and BMP-9 and stimulate recruitment, proliferation, and differentiation of osteoprogenitor cells to mature osteoblasts and partake in normal bone homeostasis. 7 BMP-2 is commercially available as recombinant bone morphogenetic protein 2 (rhBMP-2) and is approved for use in alveolar ridge and sinus floor augmentation, open tibia fractures in the appendicular skeleton, and lumbar spinal fusion in the axial skeleton. Preclinical studies of BMPs have demonstrated its ability to heal critical sized defects in canines 8 and clinically to be as efficacious as autograft in staged reconstruction of diaphyseal tibia fractures. 9 However, the use of BMPs with allograft in revision hip surgery or as a graft substitute in healing of metaphyseal defects after corrective osteotomies demonstrated inferior results because of bone resorption. 10, 11 Gap healing in cancellous bone with rhBMP-2 is preceded by bone resorption, 12, 13 why addition of an anti-resorptive drug to balance the anabolic and catabolic response to improve osseointegration of implants may be attractive. The approach has been proven in an experimental canine implant model 14 and demonstrated effective in healing of open long bone fractures in a rat model. 15 The anti-resorptive drug zoledronate is a nitrogencontaining bisphosphonates and a potent inhibitor of osteoclast activity. Zoledronate is clinically used to treat diseases with increased bone turnover such as Paget's disease, myeloma, and bone metastases. 16 Zoledronate binds to exposed bone mineral and remains inactive until internalized by osteoclasts through active bone resorption. 16 Systemic zoledronate exposure has proven effective in decreasing migration of acetabular sockets of total hip replacements in humans. 17 Delayed zoledronate administration decreased resorption and postponed remodeling of new bone in animal studies on fracture healing, 18 distraction osteogenesis, 19 and healing into porous implants. An optimal rhBMP-2 dose to improve healing of implants surrounded by an empty gap is not clear from previous animal studies. Positive histological and radiological results were not supported by mechanical testing. 8, 21, 22 Which is why further knowledge regarding rhBMP-2 dose effect on healing of empty periimplant gaps is needed. Therefore, our aim was to evaluate the use of a local anabolic stimulus (rhBMP-2) in combination with an anti-resorptive agent (zoledronate), at a bone-implant interface where a gap exists immediately after implantation. We hypothesized that with a background of delayed systemic zoledronate exposure, in experimental implants surrounded by a 0.75 mm empty gap, coating the implant surface with one of three rhBMP-2 doses (15 mg; 60 mg; 240 mg) would improve implant osseointegration compared to an untreated control implant, based on our primary endpoint: Mechanical push-out until failure of the implant-bone interface (strength; energy to failure; stiffness) and secondary endpoint: Histomorhometric fractions of tissues (new bone; lamellar bone; marrow; fibrous tissue) at the implant surface (area) and in the peri-implant gap (volume).
METHODS
The study was approved by the Institutional Animal Care and Use Committee (study ID 288-01) at North American Science Associates (NAMSA) Inc., Minneapolis, MN. Surgery, observation and bone harvest was performed at the NAMSA facility and in accordance with National Institute of Health regulations. 23 Twelve purpose-bred, skeletally mature, male mongrel/ mixed breed canines with a mean weight of 29.7 kg (range: 26.8-34.7 kg) and mean age of 17.6 months (range: 16.2-18.7 months) were used. Plane X-rays of the distal femurs confirmed closed epiphyseal plates indicating growth arrest and skeletal maturity.
The experiment was designed as a paired randomized controlled study in 12 animals, where each animal functioned as its own control. We wished to detect a minimal difference of 50% on our primary and secondary endpoints between groups. We assumed a coefficient of variance of 50% between paired differences, a two-sided a and b of 5% and 20%, respectively. This resulted in a sample size of approximately 10 animals. An additional two animals were included to prevent loss of power if animals were excluded or implantspecimens lost during evalution.
Each animal received one implant from each group, a total of four implants. The implants were inserted in the medial or lateral epicondyle of each distal femur. Through surgical overdrilling, a peri-implant gap of 0.75 mm surrounded the implant after insertion, and was maintained with endplates on deep and superficial ends of the implants. No adjuvant material was added to the gap, which is referred to here as an empty gap (Fig. 1) .
Implants
Forty-eight (48) porous coated titanium alloy (Ti-6Al-4V) implant cores and ninety-six (96) titanium alloy (Ti-6Al-4V) 7.5 mm endplates were used. The implant coating (Gription 1 ;
DePuy-Synthes, Warsaw, IN) consists of commercially pure titanium CP-Ti) titanium. With a volume porosity of 63% (AE3%) as specified by the manufacturer. The implants were cylindrical with a nominal height of 10 mm and diameter of 6 mm. Functionalization of the implant surface with rhBMP-2 was performed using sterile technique with a commercially available rhBMP-2 kit (InductOs 1 12 mg, Medtronic BioPharma, B.V. Holland). rhBMP-2 was reconstituted to a concentration of 4 mg/ml rhBMP-2 with supplied kit diluents and 150 ml of the rhBMP-2 solution was put into a well-plate (96-Well, Standard F, Sarstedt AF & Co., N€ umbrecht, Germany) blocked with a 0.5% bovine serum albumin (Bovine Serum Albumin, Sigma-Aldrich, Saint Louis, MO)/ PBS phosphate buffered salien (Sigma-Aldrich Chemie Gmbh, Steinheim, Germany) solution. All handling of the rhBMP-2 solution was performed using polypropylene pipette tips (Finntip, Thermo Fischer Scientific Oy, Vantaa, Finland). Implants were mounted on stainless steel rods and fully submerged in wells containing the rhBMP-2 solution, placed in a desiccator and subjected to vacuum to saturate the porous coating. Implants were air-dried in a vacuum, packed separately in tubes (Eppendorf LoBind Tube 1.5 ml, Eppendorf AG, Hamburg, Germany) and stored at À21˚C.
The porous coating on average retained 60 ml of fluid, resulting in an estimated total dose of 240 mg rhBMP-2 with a 4 mg/ml rhBMP-2 solution. The 15 and 60 mg implants were processed similarly, with an accordingly diluted rhBMP-2 solution. A separate in-vitro elution study confirmed release of rhBMP-2 from coated implants. Cummulated release was calculated as described by Strobel et al. 24 and was within expected range (Supplementary Material; Figs. S1-S3).
To minimize a potential neighboring effect of rhBMP-2, treatments were block-allocated with untreated and 15 mg implants on one limb and 60 and 240 mg implants contralaterally. To avoid a potential bias from site and obtain a uniform distribution, treatment was assigned with random start and systematically altered between sides of femurs and epicondyles within and between block-allocations. Animals served at the same time in two other studies in anatomical separated sites; which investigated the effects of rhBMP-2 with anti-resorptive treatment, on implants surrounded by bonegraft (proximal humeri) or direct bone contact (proximal tibias). A possible interference with the present study is addressed in the Discussion section. 
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Statistical Analysis
Statistical analysis was performed using STATA software (StataCorp, Lake Way Dr, TX, USA, version IC 13.1). Data were evaluated by repeated measures ANOVA and hypothesis were tested using post hoc test. Model assumptions were diagnosed by visual inspection of residuals and fitted values using QQ and scatter plots. Mean estimates and mean differences are presented with 95% confidence interval (CI). Non-normal distributed data were evaluated with Friedman repeated measures analysis of variance followed by Wilcoxon Signed rank-test. Median and inter quartile range (IQ) of the data are presented. Only data that passed repeated measures ANOVA or Friedman repeated measures analysis were analyzed with post hoc test or Wilcoxon signed-rank test. p values <0.05 was considered significant.
Surgery
Surgeries were undertaken using sterile technique and general anesthesia. Anesthesia was induced with acepromazine IV (0.05 mg/kg), propofol IV (1.5 mg/kg) and sustained with isoflurane (1-5% inhalant). With the animal in a supine position, at the level of the femur condyle, a 4 cm incision exposed the apex of an epicondyle. Periosteum was removed and a 2.5 mm Kirschner-wire was inserted perpendicular to the bone at the apex of the epicondyle. A 12 mm deep hole was drilled with a 7.5 mm cannulated drill, at a speed of 2 Hz to avoid inflicting thermal trauma. Debris was manually removed and remaining periosteum at the cortical edge was trimmed off, before irrigating the cavity with saline. An implant with attached endplate was inserted endplate first into the cavity and a second endplate was mounted at the superficial, cortical level ( Fig. 1 ). This secured concentric implant placement in a 0.75 mm empty gap between the cancellous bone and implant surface. Soft tissues were closed in layers with absorbable sutures. An identical procedure was performed at the opposite ipsilateral epicondyle and in the epicondyles of the contralateral femur. The procedure was performed in a fixed order starting with the untreated implant, followed by 15, 60, and 240 mg implants (to avoid contamination from rhBMP-2 by agent or dose).
Peri-operatively, animals received 15 mg/kg of cefazolin IV, and post-operatively 1 g of ceftrixone SC for 5 days as infection prophylaxis. Analgesia was obtained with marcaine with epinephrine (0.5%) applied at the incisions at the time of closure and SR buprenorphine SC (0.03 mg/kg) and acetaminophen (15 mg/kg) daily. Ten days after surgery, all animals received 0.1 mg/kg of zoledronate IV (Zolendronic Acid, Actavis Group, Iceland). Animals were allowed full weight bearing immediately after surgery. After a 4-week observation period, animals were sedated with acepromazine IV (0.5 mg/kg), anesthetized with propofol IV (4 mg/kg), and euthanized with a dose of hyper-saturated barbiturate IV (Socumb, Med-Pharmex Inc., CA).
Specimen Preparation
The distal femurs with implants in situ were harvested and stored at À21˚C until specimen preparation. All specimen preparations were performed blinded. After thawing, bone cubes with single implants were cut from each femur condyle using a water-cooled and lubricated diamond band saw (Exakt Apparatebau, Nordstedt, Germany). The most-cortical 1 mm of the implant was discarded. The remaining implant was divided into two parts by a cut perpendicular to the long axis of the implant. The most-superficial 3 mm section was stored at À21˚C for later mechanical testing. The remaining 5.5 mm innermost section was used for histomorphometric evaluation.
Histomorphometry
Specimens were gradually dehydrated in graded ethanol (70-96%), 100% iso-propyl alcohol, defatted with xylene, and finally embedded in methyl methacrylate (product no. 800590; Merck, Darmstadt, Germany). Four 30 mm slides were cut from each specimen with a hard tissue microtome (KDG-595, MePro Tech, Herhugowaard, Holland) into verical uniform random sections parallel to the central part of the axis of the implant. 25 The distance between each section was 400 mm, corresponding to the width of the blade. The specimens were stained with 0.1% toluidine blue (pH 7, SigmaAldrich, St. Louis, MO), rinsed, and mounted on glass. Blinded histomorphometric evaluation was performed using stereological software (new CAST version 3.0.9.0, Visiopharm Integrator System, Hoersholm, DK) and a light-microscope (Olympus, Ballerup, DK). The stain and technique 26 allows for differentiation of mature bone, woven bone, fibrous tissue, and marrow (Fig. S4) . Ongrowth of tissue was defined as tissue in direct contact with the implant surface. The surface area fraction of tissue coverage was performed assessing the number of intersections at the bone/implant interface by line-interception technique, 27 and tissue volumes fractions were determined by point-counting technique. 28 Application of these techniques secures highly reliable estimates with negligible bias. 29 Histomorphometry was evaluated in two regions of interest (ROIs), one in the peri-implant gap (ROI 1) and one outside the implant gap (ROI 2). Both ROI's ranged along the length of the implant axis excluding 500 mm at the ends. ROI 1 began at the median thickness of the implant coating and extende 1,000 mm out in the periimplant gap. ROI 2 began 1,500 mm from the median thickness of the implant coating and extende 1,000 mm out into host bone.
Mechanical Testing
Using a MTS Bionics test rig (MTS Systems Inc., Eden Prarie, MN) implants were tested by axial push-out to failure of the bone-implant interface. Thawed bone-implant specimens were centered over a 7.4 mm opening, ensuring 0.7 mm distance between the support jig and implant surface. A 5 mm in diameter cylindrical test probe applied an axial force at the upward facing cortical side of the bone-implant specimen. A 2 N preload defined contact position. Displacement rate was 5 mm/min. Load (N) and displacement (mm) were recorded every 10 mm, producing a load/displacement curve. Load-displacement curves were normalized to implant surface area to counter for differences in specimen height. Maximum shear strength (MPa) was defined as the peak of the stress-displacement curve at failure of the implant-bone interface, total energy absorption (J/m 2 ) as the area under the curve until failure of the bone-implant interface, and apparent shear stiffness (MPa/mm) was the maximum slope of the stress-displacement curve before the first peak.
RESULTS
All animals were fully ambulatory and weight bearing within 2 days postoperatively. One animal sustained a superficial infection at the incision site on the stifle joint and was treated with 5 days of antibiotics. A second animal developed a hematoma at the stifle incision site at the 2nd postoperative day that resolved with light compression. All animals completed the study and all specimens were available for mechanical and histomorphometric analysis. No signs of infection were present at termination and swabs taken from all implants at bone harvest were negative.
Mechanical
On a background of systemic zoledronate exposure, 15 mg implants had significantly better mechanical fixation on all measured parameters compared to any group. Maximum shear strength was 115-163% higher compared to the other groups. Total energy absorption was 91-235% higher and apparent shear stiffness was 122-203% higher compared to the other groups. No significant differences were detected between the untreated control, 60 or 240 mg implants (Fig. 2 and Table 1 ).
Histology
All implants had on-growth of new bone onto the implant surface and into the peri-implant gap but there were clear and distinct variations (Fig. 3) . The 15 mg implants had the largest implant surface area of new bone (Fig. 3c and d) . The proportion of unmineralized bone to new bone appeared to increase with rhBMP-2 dose (Fig. 3e-h ). The formation of new bone in host cancellous bone was primarily appositional with occasional inter-trabecular bone formation.
Implant Surface
With systemic zoledronate exposure, 15 mg implants had a statistically significantly higher bone ongrowth compared to any group, with a mean difference ranging from 5% to 8%. Ongrowth with other doses did not demonstrate significant differences (Fig. 4 and Table 2 ).
Implant Gap
In the peri-implant gap, 15 mg implants had a higher volume fraction of new bone compared to any other group, with a mean difference ranging from 1% to 6%. The mean difference was statistically significant when compared to 60 and 240 mg implants. No significant difference was detected between 15 mg implants and untreated control implants (Fig. 4 and Table 2 ).
Bone Outside Drill Hole
Outside the peri-implant gap the volume of new bone increased with rhBMP-2 dose. The 240 mg implants had the highest volume of new bone compared to any other group, with a mean difference ranging from 3% to 8%. Within the rhBMP-2 implants a significant mean difference of 4% was detected only between the 240 mg implants and 60 mg implants. All rhBMP-2 implants had a statistical significant higher volume of new bone when compared to the untreated control implants (Fig. 4 and Table 2 ). A reverse trend was seen with decreasing volumes of lamellar bone with rhBMP-2 dose increments; however, this was not statistically significant (Fig. 4 and Table 2 ).
Fibrous tissue was predominantly present in the untreated control group (median fraction <4% in terms of both surface area coverage (Wilcoxon signed rank test: p ¼ 0.3173) and volume fraction (Friedman: p ¼ 0.07). The median value of the untreated control group implants was primarily caused by two implants with abundant fibrous tissue formation (surface area: >68%; volume fraction: >11%).
All mechanical parameters were positively and significantly correlated with surface area coverage of new bone and volume of new bone in the peri-implant gap (Table 3) .
DISCUSSION
The purpose of the study was to investigate if implant osseointegration depended on dose of a local anabolic stimulus (rhBMP-2) with accompanying systemic antiresorptive therapy.
No evidence on any clear dose-related response between the different rhBMP-2 doses applied was detected on any of the primary mechanical endpoints or secondary histomorphometric endpoints. However, the mechanical results mirrored the observed formation of new bone well. The 15 mg implants had the best overall combination of new bone formation in three sections (surface, in gap, and outside gap) in continuity with one another, translating with statistical significance into the best mechanical fixation on all mechanical parameters.
Histology confirmed a large ongoing intra-membraneous bone formation and lesser resorption of newly formed bone in the peri-implant gap, indicating that remodeling is occurring but has been slowed down (Fig. S4) .
Bone healing around stable implants occurs by intramembraneous bone formation. Metaphyseal fracture healing is suggests to also rely on condensation of osteoblast progenitor cells between existing host trabeculae termed inter-trabecular healing. 30 Intertrabecular healing in host bone was also seen in a canine study on back-side defect healing in pressfit BMP-2 BISPHOSPHONATE DOSE-RESPONSE EMPTY GAP seated acetabular components with ceramic graft putty and rhBMP-2. 31 With the morphologic resemblance and timely proximity to inter-trabecular bone healing in adjacent host bone see in this study (Fig. 3c) ; healing of a peri-implant defect could also depend on inter-trabecular bone formation besides uni-and bi-directional appositional bone growth.
The model used in this experiment is simple, surgically controlled, and reproducible and has a reduced number of variables potentially affecting the outcome (thereby reducing variance). The model's simplicity results in limitations, which must be kept in mind when interpreting the results. This model specifically addresses healing around primary unloaded implants with a surgically created gap adjacent to the cancellous bone bed, and with no added auto-or allograft. Impaction grafted or revision implants could demonstrate different findings. The 0.75 mm gap enables us to evaluate critical distances of close but not intimate contact between implant surface and bone bed. Since the model is unloaded and not subjected to synovial fluid nutrition and hydrodynamic pressure, it does not expose the implant to all the environmental influences seen clinically.
A 4-week observation period was chosen since it displays initial bone formation before remodeling starts and can distinguish effects of therapeutic treatments relevant for initial implant fixation. 3, 29, [32] [33] [34] [35] Extrapolation to effects outside this timepoint are speculative and beyond the study scope.
Canines have served as a valuable experimental model for human bone due to their close resemblance in composition and remodeling to human bone. 36, 37 The higher remodeling rate present in young canines with good bone quality, warrants caution when interpreting the results, because normal recipients of joint arthroplasties are older and have poorer bone stock. 37 The rhBMP-2 doses used are not interchangeable with human clinical use, because interspecies differences on dose-effect exists, with higher doses required in both non-human primates and humans compared to canines, ovines, rabbits, and mice in descending order. 13, 21 It can be considered a weakness of the study that a control group without zoledronate exposure was not included. We chose to do so based on previous results obtained from the implant model. In two previous studies, using a similar empty gap model, systemic alendronate administration had no effect on implant fixation compared to control implants. 34, 38 Because zoledronate is a more potent bisphosphonate than alendronate, only a single zoledronate (0.1 mg/kg) dose was administered, compared to previous studies 0.5 mg/kg oral alendronate daily for 10 weeks. In two other canine implant studies investigating BMP-2 the initial implant fixation decreased if an anti-resorptive agent was not used. 14, 39 This necessarily requires our results with rhBMP-2 to be interpreted in the context of systemic zoledronate.
Zoledronate was chosen because it is the most potent bisphosphonate and dose was based on clinical application. 16 Local zoledronate exposure has a positive effect on mechanical fixation and osseointegration when applied to press-fit seated implants. 33, 40 However, bisphosphonates remains highly localized after administration. 41 We aimed for a uniform anti-resorptive exposure of the implant gap, which is why systemic zoledronate exposure was used.
Concern on effects from other implant sites as well as unrelated studies performed in the same animals are relevant. Effects can be divided into local effects due to the Regional Acceleratory Phenomenon (RAP) and systemic effects from distant sites. Two drill holes in each femur could influence osseointegration by RAP as described in diaphyseal bone healing, where a regional increase in remodeling rate away from the injured site occurs due to a noxious stimulus. 42 A study in sheep with implants seated in cancellous bone in the distal femur revealed no effect on bone 3 mm from the surface of the implants. 43 Implants in the presented study were separated by approximately 1 cm of cancellous bone and partly separated by the intercondylar notch (Fig. 1) .
A systemic generalized bone anabolic response to distant sites have been described with local application of the growthfactor TGF-ß2 in a canine implant study 44 and a study with surgical injury induced to diaphyseal bone in rats. 45 The systemic anabolic response to injury in rats was demonstrated to depend on the magnitude of the surgical insult. Bone marrow ablation, but not injury limited to cortical bone, induced distant bone anabolic effects. A later study in rats 46 demonstrated that the bone anabolic effect induced from distant site injury, is caused by regeneration of the bone marrow in the affected limb. If the marrow was not allowed to regenerate, by physical blocking the marrow cavity, the anabolic response failed. In our study, the drill holes were filled with implants, and the magnitude of surgical injury was less than bone marrow ablation but more than cortical injury alone. The resulting effect from distant surgical sites both in relation to this study and from other studies performed at the same time cannot be excluded. If present, we expect an effect to be moderate. Importantly, it would contribute in a similarly degree and magnitude at all sites and only abate differences between groups. In summary, all implants BMP-2 BISPHOSPHONATE DOSE-RESPONSE EMPTY GAP were subjected to an equal stimulus from both RAP and distant application of growth factors, as well as injury in number and magnitude. Potential confounding influences were thus equally and uniformly distributed among all implants, which is why RAP and systemic effects from distant sites were not expected to induce confounding bias into the results. Clinically, rhBMP-2 is applied to an absorbable collagen sponge (ACS) and used as a graft substitue. 47 We aimed for a fast release of rhBMP-2 and because collagen has bone anabolic effects, 35 which is why an ACS was omitted and rhBMP-2 was applied directly to the implant surface as proven feasible in previous studies. 22 Pure titanium is covered with a thin oxide layer that is highly biocompatible and readily adsorbs proteins to its surface. 48 Functionalization of the implant surface with rhBMP-2 thus depended on a combination of direct adherence to the titanium surface and physical restraint of the rhBMP-2 solution in the porous implant coating. Both release and dose of rhBMP-2 was confirmed by a release study (Supplementary Material; Figs. S1-S3).
Anti-resorptive control seems to be pivotal when applying rhBMP-2 to implants in a cancellous bone bed to protect newly formed bone from resorption. The enlarged gap boundary observed in 240 mg implants (Fig. 3g) coincides with a lower volume of lamellar bone outside the original drill boundary. Even with systemic zoledronate, the original cavity enlarged over 4 weeks due to bone resorption. This is consistent with other studies reporting lower bone volume with higher doses of rhBMP-2 without antiresorptive therapy. 13, 39 High doses of rhBMP-2 without adequate anti-resorptive control can thus be considered as potentially detrimental for the initial fixation of press-fit implants, since the areas of contact between a press-fit implant and the surrounding cancellous bone bed are subjected to an increase in osteoclast activity.
In summary, at an early time point of 4 weeks in an experimental implant with an unaugmented periimplant gap and addition of the anti-resorptive agent zoledronate by systemic exposure, within a narrow rhBMP-2 dose range our results demonstrate opposite effects on osseointegration, as evaluated by mechanical fixation and new bone formation. Whether different administration time points, dosages and exposure routes of zoledronate in combination with rhBMP-2 would have different results is unknown. Further preclinical investigation is needed before determining if this combination therapy approach (systemic antiresorptive and local anabolic) is beneficial to use in clinical settings where fixation is expected to be tenuous.
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